EWA
CTMX icon

EverSource Wealth Advisors’s CytomX Therapeutics CTMX Stock Holding History

EverSource Wealth Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289 Buy
+77
New +$294 ﹤0.01% 4207

Other funds holding CTMX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
AGP
Aspire Growth Partners Miromar Lakes, Florida $172M AUM 33.61% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EverSource Wealth Advisors's CTMX Position: Q2 2026 in Review

EverSource Wealth Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 77 shares worth $289. The stake represents ﹤0.01% of the portfolio and ranks #4207 among its holdings.

27 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • EverSource Wealth Advisors held 77 shares of CytomX Therapeutics worth $289 as of Q2 2026.
  • CytomX Therapeutics was a new EverSource Wealth Advisors position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4207 holding.
  • 27 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.